Opko
Opko Health Q1 Revenues More Than Double Due to COVID-19 Test Demand
The company reported revenues of $545.2 million compared to $211.5 million in the year-ago quarter, primarily driven by COVID-19 testing.
BioReference Labs Inks Deal to Provide Rapid PCR, Point-of-Care COVID-19 Testing for MLB
The firm is using Mesa Biotech's Accula system for the testing, beginning Thursday, the start of the 2021 MLB season.
Opko Health Q4 Revenues More Than Double Thanks to COVID-19 Testing
The company's service revenues increased 157 percent to $457.9 million due to significant COVID-19 testing volumes, slightly offset by lower base business volumes.
Opko Health Q3 Revenues Up 87 Percent
The firm's subsidiary BioReference Laboratories performed 3.5 million COVID-19 PCR tests and 300,000 serology tests during the quarter.
As Abbott Stock Rises on EUA for Antigen Test, Competitors' Shares Take a Hit
While the market ditched shares of many other diagnostics firms, analysts said the reaction was overblown, particularly in the case of Quidel and molecular diagnostics players.
Mar 10, 2017
Oct 10, 2016
May 9, 2016
Opko Q1 Revenues Up Nearly Ninefold
Nov 10, 2015
Opko Posts Big Q3 Revenue Gain on Acquisitions
Aug 20, 2015
Opko Completes $1.47B Buy of Bio-Reference
Aug 19, 2015
Opko Signs Contract With Three Insurers
Jun 8, 2015
Bio-Reference Q2 Revenues Grow 11 Percent
Jun 4, 2015